Bay Area's Aduro Biotech Throws in the Towel on CRS-207, Will Wind Down Trials
The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies.
Source: BioSpace
The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies.
Source: BioSpace